Bronchodilator Drugs - Japan

Japan

The Bronchodilator Drugs market in Japan is expected to achieve a revenue of ¥€1.22bn in 2024.
Furthermore, there is a projected annual growth rate (CAGR 2024-2029) of 3.80%, which will contribute to a market volume of ¥€1.47bn by 2029.
When compared globally, United States is anticipated to generate the highest revenue of €16,080.00m in 2024.
Bronchodilator drug usage in Japan is on the rise, with an increasing number of patients seeking relief from respiratory conditions.

Key regions: United States, Europe, Brazil, Japan, United Kingdom

Marché

Région

Comparaison de régions

Monnaie

Analyst Opinion

Bronchodilator drugs are widely used in Japan to treat respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). The market for these drugs has seen steady growth in recent years due to various factors.

Customer preferences: Japanese consumers are increasingly aware of the importance of maintaining good respiratory health. As a result, there is a growing demand for bronchodilator drugs that can effectively treat respiratory diseases. Consumers in Japan also tend to prefer inhalers over other forms of medication, as they are easy to use and provide quick relief.

Trends in the market: One of the key trends in the Japanese bronchodilator drugs market is the growing use of combination therapies. These therapies combine two or more drugs to provide more effective treatment for respiratory diseases. Another trend is the increasing use of long-acting bronchodilators, which provide sustained relief for up to 24 hours.

Local special circumstances: Japan has a rapidly aging population, and this has significant implications for the bronchodilator drugs market. Older adults are more likely to suffer from respiratory diseases, and they also tend to have more complex medical needs. As a result, there is a growing demand for bronchodilator drugs that are tailored to the needs of older adults.

Underlying macroeconomic factors: Japan has a highly developed healthcare system, and this has helped to drive growth in the bronchodilator drugs market. The government provides universal healthcare coverage, and this has made it easier for consumers to access the medications they need. In addition, Japan has a strong pharmaceutical industry, which has helped to drive innovation in the bronchodilator drugs market. Finally, the country's aging population has also contributed to the growth of the market, as older adults are more likely to require treatment for respiratory diseases.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.